Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

San Francisco Business Times: Two JOBS Acts are better than one

scientist-eyedropper

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding the Jumpstart Our Business Startups Act (JOBS) Act for giving emerging biotech companies a much-needed boost. As Hastings points out, 80-plus companies will have gone public in the last two years with the help of the JOBS Act. As the biotech industry gathers in San Diego next month for the 2014 BIO International Convention, several CEOs in attendance will no Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

SBIR Funds Speed the Delivery of Breakthrough Treatments and Cures

scientists115x76

Today, BIO’s Executive Vice President of Emerging Companies Cartier Esham presented testimony to the U.S. House of Representatives Committee on Small Business regarding oversight of the Small Business Innovation Research and Small Business Technology Transfer Programs (SBIR/STTR). Dr. Esham emphasized that SBIR plays a critical role in supporting small biotech companies and funding their early-stage research as they navigate the “valley of death,” a critical time when the scientific concepts have shown promise but the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Forbes: Sure, We’ll (Eventually) Beat Cancer. But Can We Afford To?

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

On May 19, Paul Howard highlighted the promise of immunotherapy for the treatment and possible eventual cure of cancer but emphasized that it is critical to focus on the long-term perspective. Key points raised in the article: ‘Reducing incentives for innovation (and drug development returns are roughly comparable to those in the software industry) and you would encourage investors to park more of their capital in more lucrative investments (think: Snapchat), and less into research for Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Testifies at 21st Century Cures Hearing on PCAST

TheHill

Today, BIO’s Executive Vice President of Health Sara Radcliffe presented testimony to the U.S. House of Representatives Energy and Commerce Subcommittee on Health Hearing. The Hearing focused on the President’s Council of Advisors on Science and Technology (PCAST) Report on Drug Innovation and key issues related to the 21st Century Cures initiative to examine what steps the Committee can take to accelerate the pace of cures in America. Below is a summary: The Challenge of Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

BIO Strongly Supports R&D Tax Credit Legislation

cells115x76

The House Ways and Means Committee posted the following message on its home page showing the support of several organizations, including BIO, for the American Research & Competitiveness Act (H.R. 4438): “Today, the National Association of Manufacturers, Chamber of Commerce, R&D Credit Coalition, and Biotechnology Industry Organization – representing thousands of small and large U.S. businesses – issued their support for H.R. 4438, a bipartisan, permanent extension of the research and development (R&D) tax credit. In their call for a permanent R&D Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,